Genome profiling of ERBB2-amplified breast cancers by Sircoulomb, Fabrice et al.
RESEARCH ARTICLE Open Access
Genome profiling of ERBB2-amplified breast
cancers
Fabrice Sircoulomb
1†, Ismahane Bekhouche
1†, Pascal Finetti
1†, José Adélaïde
1, Azza Ben Hamida
1,
Julien Bonansea
1, Stéphane Raynaud
1, Charlène Innocenti
1, Emmanuelle Charafe-Jauffret
1,2,4, Carole Tarpin
3,
Farhat Ben Ayed
5, Patrice Viens
3,4, Jocelyne Jacquemier
1,2, François Bertucci
1,3,4, Daniel Birnbaum
1, Max Chaffanet
1*
Abstract
Background: Around 20% of breast cancers (BC) show ERBB2 gene amplification and overexpression of the ERBB2
tyrosine kinase receptor. They are associated with a poor prognosis but can benefit from targeted therapy. A better
knowledge of these BCs, genomically and biologically heterogeneous, may help understand their behavior and
design new therapeutic strategies.
Methods: We defined the high resolution genome and gene expression profiles of 54 ERBB2-amplified BCs using
244K oligonucleotide array-comparative genomic hybridization and whole-genome DNA microarrays. Expression of
ERBB2, phosphorylated ERBB2, EGFR, IGF1R and FOXA1 proteins was assessed by immunohistochemistry to evaluate
the functional ERBB2 status and identify co-expressions.
Results: First, we identified the ERBB2-C17orf37-GRB7 genomic segment as the minimal common 17q12-q21
amplicon, and CRKRS and IKZF3 as the most frequent centromeric and telomeric amplicon borders, respectively.
Second, GISTIC analysis identified 17 other genome regions affected by copy number aberration (CNA)
(amplifications, gains, losses). The expression of 37 genes of these regions was deregulated. Third, two types of
heterogeneity were observed in ERBB2-amplified BCs. The genomic profiles of estrogen receptor-postive (ER+)
and negative (ER-) ERBB2-amplified BCs were different. The WNT/b-catenin signaling pathway was involved in ER-
ERBB2-amplified BCs, and PVT1 and TRPS1 were candidate oncogenes associated with ER+ ERBB2-amplified BCs. The
size of the ERBB2 amplicon was different in inflammatory (IBC) and non-inflammatory BCs. ERBB2-amplified IBCs
were characterized by the downregulated and upregulated mRNA expression of ten and two genes in proportion
to CNA, respectively. IHC results showed (i) a linear relationship between ERBB2 gene amplification and its gene
and protein expressions with a good correlation between ERBB2 expression and phosphorylation status; (ii) a
potential signaling cross-talk between EGFR or IGF1R and ERBB2, which could influence response of ERBB2-positive
BCs to inhibitors. FOXA1 was frequently coexpressed with ERBB2 but its expression did not impact on the outcome
of patients with ERBB2-amplified tumors.
Conclusion: We have shown that ER+ and ER- ERBB2-amplified BCs are different, distinguished ERBB2 amplicons in IBC
and non-IBC, and identified genomic features that may be useful in the design of alternative therapeutical strategies.
Background
Gene amplification is a frequent alteration in breast can-
cer (BC) that affects multiple genomic regions [1-3].
One of the most studied amplifications is located in
chromosomal region 17q12 and involves the ERBB2
gene. ERBB2 encodes a transmembrane tyrosine kinase
receptor of the ERBB/EGFR family. ERBB2 is amplified
in around 20% of BCs. The receptor is overexpressed in
most amplified cases and in some non-amplified cases
as well. This alteration is associated with a poor clinical
outcome. BCs with ERBB2 overexpression can benefit
from a targeted therapy that uses the humanized mono-
clonal antibody trastuzumab or the ERBB kinase inhibi-
tor lapatinib [4,5]. However, resistance to trastuzumab is
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[7], although ERBB2 phosphorylation [8], PTEN and
PIK3CA status [9] seem important factors.
ERBB2 gene amplification can be detected by various
methods including fluorescence in situ hybridization
(FISH) or quantitative PCR [10]. Overexpression of the
receptor is detected by immunohistochemistry (IHC) by
using the standardized Dako Herceptest. Gene expres-
sion studies have shown that BCs with a specific gene
expression signature including ERBB2-overexpression
constitute a separate molecular subtype [11-13]. How-
ever, a substantial number of breast tumors assigned to
the ERBB2 subtype lacks ERBB2 protein expression and/
or ERBB2 gene amplification [14,15] and ERBB2-positive
cancers that express estrogen receptor (ER) fall into the
luminal subtypes [11,13,16].
Several 17q12-q21 genes are variably coamplified and
coexpressed with ERBB2 [17]. This could influence the
response to trastuzumab and/or constitute accessory tar-
gets for synergistic treatment [18-21]. A better knowledge
of ERBB2-amplified BCs may thus help design new thera-
peutic strategies. To better characterize this particular
group of BCs, we used high-resolution array-comparative
genomic hybridization (aCGH) and whole-genome DNA
microarrays to define the genome and gene expression
profiles of 54 BCs with ERBB2 amplification.
Methods
Breast cancer samples
Tumor tissues were collected from 340 patients with
invasive adenocarcinoma who underwent initial surgery
at the Institut Paoli-Calmettes (Marseille, France)
between 1987 and 2007 (from a cohort of 2,175 patients
with frozen tumor sample) and from a series of 91
Tunisian T4d tumors (TNM, UICC) treated between
1994 and 1998 at the Salah Azaiz Institute (Tunis, Tuni-
sia). Each patient gave informed consent and the study
was approved by our institutional review board (also
called “COS”). Samples were macrodissected and frozen
in liquid nitrogen within 30 minutes of removal. The
panel was not made of consecutive tumors but enriched
in various forms of BCs. These include inflammatory
BCs (IBCs), non-inflammatory BCs (NIBC), very young
women BCs (YWBCs, ≤ 35 years) and older women BCs
(OWBCs, ≥ 45 years).
The 340 tumors were analyzed by high resolution
aCGH 244K in our previous studies [[3,22], unpublished
data]. In all these cases, profiled samples were always
collected before any systemic therapy (chemotherapy,
hormone or trastuzumab therapy). They corresponded
to a tumor surgically removed for NIBCs, and to the
diagnostic surgical biopsy for IBCs. A total of 54 (16%)
cases presented amplification of the ERBB2 locus. Fea-
tures of these ERBB2-amplified tumors are reported in
Additionnal file 1-Table S1. All specimens contained
>60% of tumor cells (as assessed before RNA extraction
using frozen sections adjacent to the profiled samples).
IHC data included status for estrogen and progesterone
receptors (ER and PR), P53 (positivity cut-off value of
1%), ERBB2 (0-3+ score, DAKO HercepTest kit scoring
guidelines, defined as positive with 3+ and 2+ controled
by FISH according to ASCO guidelines), and Ki67 (posi-
tivity cut-off value of 20%).
Cell lines
Fourteen BC cell lines with ERBB2 amplification (BT-
474, HCC202, HCC1569, HCC1954, HCC2218, JIMT-1,
MDA-MB-361, MDA-MB-453, SK-BR-3, UACC-812,
UACC-893, ZR-75-30 [23], SUM-190 and SUM-225
[24]) were grown as recommended by their supplier.
These cell lines have been studied by FISH and QPCR
and tested for trastuzumab response [8]. Most have also
been previously studied by aCGH [25].
DNA and RNA extraction
DNA and RNA were extracted from frozen samples by
using guanidium isothiocynanate and CsCl gradient, as
previously described [26]. RNA integrity was controled
on Bioanalyzer (Agilent Technologies).
Array-comparative genomic hybridization (aCGH) and
expression data analyses
Genomic imbalances were determined by aCGH using
244K CGH oligonucleotide microarrays (Hu-244A, Agi-
lent Technologies). Comparison of the results obtained
with FISH and aCGH for several gene amplicons
demonstrated a perfect agreement between the two
techniques [3]. Gene expression data of 51 of the 54
BCs and 4 normal breast (NB) samples (NB1, NB2, NB3
and NB4, representing samples from 4 women and 3
commercial pools of respectively 1, 2 and 4 normal
breast RNA, Clontech, Palo Alto, CA) were quantified
by using whole-genome DNA microarrays (HG-U133
plus 2.0, Affymetrix). Experiments and data analyses
were done as described [3]. Microarray data were depos-
ited in Gene Expression Omnibus (GEO) under the fol-
lowing name: GSE 17907. To identify significant altered
regions through the whole genome, we used the GISTIC
algorithm to score the Copy-Number Genome across
the 54 BCs [27] with a bootstrap procedure to calculate
the significance level. Established for each genomic seg-
ment, this score takes into account the frequency of
gene alterations (amplifications, gains, losses) and their
gene copy number level. Expression data, up- and
down- regulation were defined using normal breast
expression comparison, with a |2-fold| threshold [3].
The gene expression signature (GES) associated with
ER+ and ER- ERBB2-amplified BCs was obtained using
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assessed using resampling with 100 permutations as
described [28]. Unsupervised analysis was done with the
Cluster program using log2-transformed data [29].
Expression data were median-centred on genes. For
aCGH analysis, we evaluated robustness of clusters
using multiscale bootstrap resampling; the robustness of
each cluster was estimated with the R-package pvclust
[30] using Ward’s agglomerative method, Euclidean dis-
tance and 1000 bootstrap replications as parameters.
Pvclust provides AU (approximately unbiased) p-values
computed by multiscale bootstrap resampling. Cluster
agglomerative parameters were centroid-linkage for
expression [13]. Pearson correlation was used as similar-
ity metrics for both of them.
Details concerning statistical methods are given in
Additionnal file 2.
Pathway/network analysis
The biologic relevance of the data was estimated using
the Ingenuity Pathway Analysis (IPA) software (Ingenu-
ity Systems) [31]. This functional annotation and net-
work-mapping tool enables the discovery, visualization,
and exploration of biologically and therapeutically rele-
vant networks of gene interactions from the experimen-
tal data. Focus genes were imported using their Entrez
Gene ID to be mapped to the Ingenuity database. The
identified genes were mapped to genetic networks avail-
able in the Ingenuity database and were then ranked by
the probability that a collection of genes equal to or
greater than the number in a network could be achieved
by chance alone. Confidence level of 99.9% was chosen
as cut-off. Ingenuity® software [31] was then used to
identify canonical pathways and networks.
Immunohistochemistry (IHC)
IHC was done using commercially available mouse
monoclonal antibodies directed against human ERBB2,
FOXA1, phosphorylated ERBB2 (pERBB2), IGF1R, and
EGFR (Additionnal file 1-Table S2). The HercepTest
(DAKO) is directed against the intracellular region of
ERBB2 with high sensitivity; TAB250 anti-ERBB2 recog-
nizes with high specificity but low sensitivity the extra-
cellular region of the receptor [10]. Phosphorylated
ERBB2 status was assessed using monoclonal mouse
anti-human HER2-pY-1248 with CSA II biotin-free tyra-
mide signal amplification system (DakoCytomation) as
described [8].
IHC was done on 5-μm sections of tissue fixed in
alcohol formalin for 24 hours and embedded in paraffin
as described [32], using LSAB
R2 kit in the autoimmu-
nostainer (Dako Autostainer). According to a previous
study [33], effects of fixation in this condition time
would not affect the immunohistochemical detection of
hormone receptors in breast cancer. The optimal titer
for each antibody (except for HercepTest and G11
directed against ERBB2 and IGF1R, Additionnal file 1-
Table S2) was established based on negative and positive
controls. In addition, the dilution took into account the
expected topography of the immunostaining (nucleus,
cell membrane, and cytoplasm). After staining, slides
were evaluated by two pathologists (J.J. and E.C.J.).
Results for EGFR, pERBB2, FOXA1 and IGF1R status
were scored by the quick score (QS) [32], taking into
account the percentage (P) and intensity (I) of immu-
nostaining (QS = P × I varies from 0 to 300) except for
ERBB2 status (defined with ERBB2 TAB250 or Her-
cepTest kit), which was evaluated with the Dako scale
(0-3+, HercepTest kit scoring guidelines). Discrepancies
were resolved under multiheaded microscope. We chose
a uniform and clear cutoff value of QS > 0 for all anti-
bodies, except for ERBB2 where the HercepTest scale
was used: negative 0-1+ and positive 2+ and 3+.
Statistical analyses
A s s o c i a t i o n so fE G F R ,E R B B 2 ,p E R B B 2 ,F O X A 1a n d
IGF1R expression with histoclinical features were
assessed with Spearman’s rank-correlation test or
Mann-Whitney U test, as appropriate. Overall survival
(OS) time was defined as the period from the date of
starting first-line chemotherapy until the date of death
from any cause or until the date of the last follow-up, at
which point data were censored. Metastasis-free survival
(MFS) was defined by the time interval between the
diagnosis of BC and a distant metastasis. Metastasis-free
patients were right censored at the date of the last fol-
low-up, death, recurrence of local or regional disease, or
development of a second primary cancer. Kaplan-Meier
method was used to plot OS or MFS curves according
to IHC results, and the significance of differences was
assessed with the log-rank test. Univariate and multi-
variate Cox proportional hazard models were used to
estimate the relations of protein expressions and clinical
characteristics to OS. All reported p-values were two-
s i d e d ,a n dt h el e v e lo fs i g n i f i c a n c ew a ss e ta tp<0 . 0 5 .
Variables for multivariate analysis were selected by
means of a forward stepwise approach, using a signifi-
cance level of p < 0.10 for entering into or remaining in
the model. All analyses were done with the software
package StatView, version 5.0 (SAS Institute, Inc.).
Results
Characterization of ERBB2-amplified BCs and cell lines
From our previous aCGH studies [[3,8,22], unpublished
data], we identified 54 tumors and 14 cell lines exhibit-
ing regional 17q12-q21-amplification (with a threshold
log2 ratio >1) centered on ERBB2 (Additionnal file 3-
Figure S1A-C and S1D, respectively). The ERBB2
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our panel was close to the frequency values obtained in
previous studies [34-37].
By using two different threshold values (log2 ratio
>|0.5|, and |1|), we distinguished low-level CNAs, which
can result from aneuploidy, from high-level CNAs,
which result from focal amplification or deletions of
chromosome regions. Using the GISTIC algorithm, the
17q12-q21-amplicon exhibited the highest score index
because it was the most frequently amplified with the
highest level of amplification. In agreement with pre-
vious reports [1,37], the frequency plot analysis showed
additional regions of recurrent gene copy number gains
and amplification including 1q22-24, 8p12, 8q21-24,
11q13, 17q, 20q13.3 regions (Figure 1).
The histoclinical features and molecular subtypes of
the 54 ERBB2-amplified BCs are listed in Additionnal
file 1-Table S1. They contained 20 IBC and 34 NIBC as
well as 10 and 21 primary breast tumors of young (≤ 35
years) and older women (≥45 years) (YWBC and
OWBC, respectively). The presence of IBC samples
among the 54 ERBB2-amplified tumors reflects the fact
that IBCs do comprise a large proportion of ERBB2 can-
cers. The ERBB2-amplified cases were mainly ductal
tumors with pathological grade 3, high expression of
ERBB2, TP53 and high Ki67 proliferative index. More-
over, 53% and 6% of the ERBB2-amplified BCs were of
ERBB2-like and luminal B subtypes, respectively.
Heterogeneity of ERBB2-amplified tumors
We first established the unsupervised hierarchical clus-
tering of the 54 samples and the 225,388 aCGH oligonu-
cleotide probes (excluding X and Y chromosomes)
(Figure 1). The samples were separated in two groups (I
and II) of 26 and 28 samples, respectively. Histoclinical
features were compared between the two groups except
for TP53 and Ki67 status because of a too low number of
informed samples. For the other histoclinical features, no
difference was observed between the two groups except
for ER expression (p < 0.05) (Additionnal file 1-Table
S3). These results showed heterogeneity of ERBB2-ampli-
fied tumors with at least two categories, ER- and ER+.
ER and PR status were not available for seven samples
(Figure 1). To evaluate the robustness of the clusters, we
established the hierarchical clustering without these
seven samples (data not shown) and compared it with
the clustering analysis including them. The results
showed a similar distribution (accuracy = 98%) and con-
firmed that ER+ and ER- ERBB2-amplified breast cancers
are different (Fisher exact’s test, p = 0.019; O.R. = 4.39).
We focused on the profiles of chromosome 17 long
arm (Figure 2). Unsupervised hierarchical clustering of
the 54 samples and the 5,574 oligonucleotide probes
covering 17q (Figure 2) separated the samples in two
groups (I and II) of 28 and 26 samples, not different
with respect to histoclinical features. This separation
was influenced by the amplicon size and the gene copy
number associated with the multiple amplifications on
17q. The GISTIC score based on the calculation com-
bining CNA frequency and gene amplification level
showed that only the 17q12-q21 (pink box) amplicon
centered on the ERBB2 locus was significant (p < 0.001)
(Figure 2).
By next focusing on a smaller interval comprised
between AATF and STAT3 genes (Figure 3), we found
that the ERBB2-amplicon size varied within a region
delimited by DDX52 and KRT40 genes from centromere
to telomere, respectively (Figure 3). Hierarchical cluster-
ing of the 54 samples and the 650 oligonucleotide
probes covering this region separated the samples in
two groups (I and II) of 20 and 34 samples, respectively.
The ERBB2-amplicon size was larger in group I than in
g r o u pI I .A ss h o w ni nF i g u r e3 ,I B C sh a das m a l l e r
amplicon than NIBCs, and hormonal receptor negative
tumors (ER- and PR-) a smaller amplicon than hormo-
nal receptor positive tumors (ER+ and/or PR+) (p =
0.04 and p = 0.03, respectively) (Additionnal file 1-
Table S4). Group II contained twice more IBC tumors
than group I. IBCs have a poorer prognosis than
NIBCs. The absence of 5-year MFS difference between
the two groups suggested that the presence of the
ERBB2-amplicon influences the NIBC phenotype and
g e n e r a t e si nN I B C st h es a m ep e j o r a t i v ee v o l u t i o na s
that observed in IBCs.
Taken together, our results identified two types of het-
erogeneity within ERBB2-amplified tumors, i.e. with
respect to ER status and to IBC/NIBC clinical forms.
To evaluate the potential impact of the ER status on
the amplicon size changes linked to IBC and NIBCs, we
repeated the analysis using ER- and and ER+ grade-
matched IBC and NIBC samples. The number of grade
1a n d2t u m o r sE R -a n dE R +I B Ca n dN I B Cs a m p l e s
was too low to be compared in such analysis. Therefore,
21 samples of grade 3 ER- IBC (N = 10) and NIBC (N =
11) were compared (data not shown). The results
s h o w e dt h a tg r a d e3E R -I B C sh a v eas m a l l e rERBB2-
amplicon than grade 3 ER- NIBCs. A similar result was
obtained with grade 3 ER+ IBC (N = 7) and NIBC (N =
6) samples (data not shown). These results suggest that
the size of the ERBB2 amplicon is smaller in IBC than
in NIBC and that this is independent of the ER status.
Size, core and magnitude of the ERBB2-amplicon
To better define the ERBB2-amplicon, we extracted the
data associated with gene copy number amplification for
the 54 BCs and the 14 cell lines within the region com-
prised between AATF and STAT3 (Additionnal file
1 - T a b l eS 4 ) .F o re a c ho ft h e5 4s a m p l e s ,w ep r e c i s e l y
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of the ERBB2-amplicon by measuring the log2 ratio for
each oligonucleotide of the region (Additionnal file 1-
Table S5). The amplicon borders were defined as first
genes targeted by amplification at the centromeric and
telomeric locations of the ERBB2-amplicon. PLXDC1,
FBXL20, MED1, CRKRS and STARD3 were identified as
frequent centromeric borders and IKZF3, PSMD3,
THRA, WIPF2, CDC6 and RARA as frequent telomeric
borders. Overall, CRKRS and IKZF3 were the most fre-
quent centromeric and telomeric borders, respectively.
The ERBB2-C17orf37-GRB7 genomic segment was
systematically amplified in all ERBB2-amplified samples
and constitutes the core of the amplicon.
Figure 1 aCGH profiling of ERBB2-amplifed BCs. Unsupervised hierarchical clustering of genome copy number profiles measured for 54
ERBB2-amplified primary breast tumors by aCGH on 225,388 probes (without X and Y). Red indicates increased genome copy number and green
indicates decreased genome copy number. The bars to the left indicate chromosome locations with chromosome 1pter to the top and 22qter
to the bottom. The location of the odd-numbered chromosomes is indicated at left. The vertical orange dotted line defines the limits of the two
major sample clusters defined by their respective AU (approximately unbiased) p-values Below the dendrogram, name of tumors are given and
the rows indicate their ER and PR IHC status (black square, ER+ or PR+; white square, ER- or PR-). CNA frequencies discriminate ER+ and ER-
ERBB2-amplified breast tumors (see also Additionnal file 1-Table S3). On the right, frequencies of CNA (gains and losses) are plotted as a function
of chromosome location. Horizontal lines indicate chromosome boundaries. Positive and negative values indicate frequencies of tumors showing
copy number increase and decrease, respectively, with gains and losses as described in the method section.
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averages by aCGH in 22 ER+, 25 ER-, 20 IBC and 31
NIBC cases. They were equal to 11.2, 10.7, 10.5 and
11.8 respectively, indicating that the magnitude of the
amplification is not different in the different entities.
Chromosomal regions altered by CNAs in ERBB2-amplified
tumors
To identify other regions frequently targeted by CNA
in the ERBB2-amplified tumors, we used the GISTIC
algorithm. In addition to the 17q12-q21 amplicon, the
score index pointed to 17 other regions affected by
CNAs (p < 0.001) (Additionnal file 1-Table S6A)
including six regions of gain (1p36.33-p36.32, 4q13.3,
8q23.3-q24.21, 11q13.5-q14.1, 14q11.1-q11.2, 19q12)
and eleven regions of loss (4p16.3, 7p22.3, 8p23.3-
p23.2, 8p11.23-p11.22, 9q34.3, 10q26.3, 11p15.5,
14q32.33, 15q11.2, 16p13.3, 19p13.3). Including the
17q12-q21 genes, a total of 282 genes were targeted
(Additionnal file 1-Table S6A). Regions 4q13.3, 8q23.3-
q24.21, 11q13.5-q14.1, 14q11.1-q11.2, 17q12-q21.2,
19q12 were also amplified.
Figure 2 17q12-q21-amplicon as the most significant on 17q. Unsupervised hierarchical clustering of genome copy number profiles
measured for 54 ERBB2-aplified primary breast tumors by aCGH on 5,574 17q probes. Legend is similar to Figure 1. The bar to the left indicates
chromosome 17q location with centromere to the top and qter to the bottom. Below the dendrogram, name of tumors are given and the rows
indicate their ER and PR IHC status (black square, ER+ or PR+; white square, ER- or PR-). Color codes and corresponding legends are indicated in
the box located to the top right. On the right, combining the CNA frequency and gene amplification level, the GISTIC algorithm plotted the
score index as a function of chromosome location. AATF and STAT3 delineate the genomic fragment that defined the ERBB2-amplicon. The green
line indicates the threshold of significance for the score. Previous studies have reported that the 17q arm is the site of multiple amplicons. They
are indicated by black bars at the right of the plot score. The Figure shows only 17q12-q21 (pink box) centered on the ERBB2 locus as the
significant 17q amplicon (p < 0.001).
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amplified tumors
To identify genes whose expression levels were modified
in proportion to CNA, we combined aCGH and RNA
expression data for 51 samples in integrated analyses, as
described [3]. Within altered chromosomal regions, rela-
tions between gene expression and CNA level were
assessed by Pearson correlation test (p < 0.01) on genes
for which variations (at both level, gene CNA and
deregulated expression), were explained by more than
10% of tumors. The cut-off of 10% was arbitrary defined
to increase the robustness of the candidate gene selec-
tion. We then identified 1 and 36 genes whose expres-
sion levels were downregulated and upregulated in
proportion to DNA copy number losses and gains (or
amplification), respectively (Additionnal file 1-Table
S6A, genes written in bold) (p < 0.01). They were
located in 8p23.3-p23.2 (C8orf68), 8q23.3-q24.21
(C8orf53, MAL2, LOC286052, SQLE, KIAA0196),
11q13.5-q14.1 (R S F 1 ,I N T S 4 ,K C T D 2 1 ), 17q12-q21.2
(DDX52, MRPL45, SOCS7, ARHGAP23, SNIP, MLLT6,
CISD3, PCGF2, PSMB3, PIP4K2B, CCDC49, LASP1,
LOC642808, CACNB1, LOC90110, FBXL20, MED1,
CRKRS, STARD3, PERLD1, ERBB2, C17orf37, GRB7,
RAPGEFL1, WIPF2, CDC6, RARA), and 19q12 (CCNE1)
regions, respectively. Some genes with correlation
between CNA and mRNA expression (Additionnal file
1-Table S6A) have been found in previous studies [1,38].
In the 17q12-q21.2 amplicon, which exhibited the
highest frequency (Additionnal file 1-Tables S6A-S6B),
amplifications combined to the upregulated gene expres-
sion of CRKRS (71%), STARD3 (82%), PERLD1 (86%),
ERBB2 (92%), C17orf37 (84%) and GRB7 (86%) were the
most frequent (Additionnal file 1-Tables S6A-S6B). This
high correlation between gene amplification and gene
expression is in agreement with a previous report [39].
Figure 3 ERBB2-amplicon size is significantly different in ERBB2-amplified IBC and NIBC. Unsupervised hierarchical clustering of genome
copy number profiles measured for 54 ERBB2-amplified primary breast tumors by aCGH on 650 17q12-q21 probes within the genomic interval
defined from centromere to telomere by [AATF-STAT3] (bar to the left) (Additionnal file 1-Table S5). Below the dendrogram, name of tumors are
given and the row indicates their ER (black square, ER+; white square, ER-) and IBC/NIBC (orange and blue boxes, respectively) status,
respectively. Corresponding legends are indicated in the box located to the top right. On the right, the scores obtained for all BCs, IBCs and
NIBCs are plotted (red, orange and blue lines, respectively) as a function of chromosome location. ERBB2-amplicon size varies within a region
delimited by DDX52 and KRT40 genes. IBCs have a smaller amplicon than NIBCs located within a region delimited by PLXDC1 and KRT40 genes.
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amplified tumors
Supervised genome profile analysis identified 43 altered
(gains and losses defined with a threshold value of log2
ratio >|0.5|) genes with a frequency different in ER- and
ER+ ERBB2-amplified BCs (Fisher exact test p ≤ 0.05
and False Discovery-Rate (FDR) corrected, Benjamini
and Hochberg FDR inferior to 25%) (Additionnal file 1-
Table S7A and Additionnal file 2-). Unfortunately, these
43 altered genes could not be validated in a separate
cohort of BCs because no high resolution aCGH data
(≥ 20,000 oligos) including ER information were avail-
able among public data.
Gains targeting GDPD4, PAK1, CLNS1A genes at
11q13.5 were associated with ER- ERBB2-amplified
BCs (Table 1). In ER+ ERBB2-amplified BCs, 40 genes
were altered by (i) copy number gain at 8p11.23 and
8q23.3-q24.21 (27 genes), (ii) amplification at 8q24.13
and 17q12-q21.1 (5 genes), (iii) both gain and amplifi-
cation at 8q24.13 (2 genes), and (iv) losses or deletions
at 1p31.33, 1p36.32, 4p16.3 and 11p15.5 (6 genes)
(Table 1). Only genes (N = 17) targeted by CNA in ER
+ ERBB2 amplified BCs were sites of genomic variation
(12 by copy number variation [CNV], 4 by insertion or
deletion [InDel] and 1 by inversion), respectively
(Table 1).
When aCGH and RNA data were combined (Addi-
tionnal file 1-Table S7A), TRPS1 and PVT1 were found
associated with ER+ ERBB2-amplified tumors (Table 1).
Gene expression and canonical pathways of ER- and ER+
ERBB2-amplified tumors
We established the gene expression profiles of 51 of the
54 samples. Hierarchical clustering did not distinguish
ER- ERBB2-amplified BCs from ER+ ERBB2-amplified
BCs (Additionnal file 4-Figure S2). The 51 BCs were
separated in two groups (I and II) of 25 and 26 cases,
respectively. No difference in ER protein expression (as
defined by IHC) was observed between the two groups
(p = 0.25) (Additionnal file 1-Table S7B). Group II con-
tained more IGF1R-expressing tumors (as defined by
IHC) and normal-like tumors than group I.
Supervised analysis of the 51 samples showed that 402
genes (corresponding to 638 probe sets) were differen-
tially expressed in ER- and ER+ ERBB2-amplified
tumors (SNR analysis with FDR <0.1%) (Figure 4). They
included 257 genes upregulated in ER- ERBB2-amplified
tumors and 145 upregulated in ER+ ERBB2-amplified
tumors (corresponding to 366 and 272 probe sets,
respectively) (Additionnal file 1-Table S7C). GATA3,
ESR1, TFF1, TFF3 and ERBB4 were upregulated,
whereas IGF2R, GATA6, EGFR and TGFA were downre-
gulated in ER+ ERBB2-amplified tumors.
Using the Ingenuity software, canonical pathways were
defined as associated with either ER- or ER+ ERBB2-
amplified tumors (p < 0.05) (Additionnal file 1-Table
S7D and Additionnal file 5-Figure S3). Genes coding for
proteins involved in WNT/b-catenin signaling pathway,
aryl hydrocarbon receptor signaling (cell cycle and apop-
tosis or nuclear receptor signaling), LPS/IL-1 mediated
inhibition of RXR function (nuclear receptor signaling)
as well as various metabolic pathways (i.e. Nicotinate
and nicotinamide, galactose, Inositol Phosphate, b-Ala-
nine) were upregulated in ER- ERBB2-amplified tumors
(p < 0.05). In contrast, among genes downregulated in
ER- ERBB2-amplified tumors (p < 0.05), some coded for
proteins involved in endothelin-1 signaling, nitric oxide
signaling in the cardiovascular system (both associated
with cardiovascular signaling pathways), NRF2-mediated
oxidative stress response (cell stress and injury pathway),
synaptic long term depression, neuropathic pain signal-
ing in dorsal horns neurons, mechanisms of viral exit
from host cells and other metabolic pathways.
Chromosomal regions altered by CNAs in NIBC and IBC
ERBB2-amplified tumors
To identify regions frequently targeted by CNA in IBC
and NIBC ERBB2-amplified tumors, we used the GISTIC
algorithm. The score index pointed to 4 gained or ampli-
fied regions (8q23.3, 17q11.1-q11.2, 17q12-q21.2 and
17q21.32-q21.33) in NIBCs and 7 gained or amplified
regions (8q24.11-q24.12, 8q24.13, 8q24.13-q24.21,
17q11.2, 17q12-q21.2, 17q21.33 and 19q12) in IBCs (p <
0.001) (Additionnal file 1-Table S7E). A total number of
172 and 113 genes were targeted in NIBC and IBC popu-
lations, respectively. Among them, 50 genes were com-
monly found altered (in bold in Additionnal file 1-Table
S7E) in the two populations. The number of genes asso-
ciated with the 17q12-q21 amplicon was lower in IBC
than in NIBC in agreement with the size difference of the
ERBB2-amplicon between the two populations.
Gene expression differences between IBC and NIBC
ERBB2-amplified tumors
We compared the expression of genes targeted by the
17q12-q21-amplicon in IBCs and NIBCs. SNIP (p =
0.0002), MLLT6 (p = 0.0072), CISD3 (p = 0.0111),
PCGF2 (p = 0.0067), PSMB3 (p = 0.0029), PIP4K2B (p =
0.0126), FBXL20 (p = 0.0324), STARD3 (p = 0.0318),
GRB7 (p = 0.0244) and RARA (p = 0.0201) were down-
regulated in ERBB2- a m p l i f i e dI B C sc o m p a r e dt o
ERBB2-amplified NIBCs. SQLE (8q24.13) (p = 0.0268)
and RSF1 (11q13.5) (p = 0.0067) were upregulated in
ERBB2-amplified IBCs.
To better understand the mechanisms associated with
gene expression deregulation of these candidates in IBC
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tions. Among the 10 genes downregulated in ERBB2-
amplified IBCs compared to ERBB2-amplified NIBCs,
we noted that SNIP and RARA were gained or amplified
in NIBCs but not in IBCs. MLLT6, CISD3, PCGF2,
PSMB3, PIP4K2B, FBXL20, STARD3, GRB7 were gained
or amplified in both populati o n s .T h i ss u g g e s t st h a t
downregulation of these 10 genes in IBC could be dri-
ven by epigenetic mechanisms differentially regulated in
the two populations. Among the 2 genes upregulated in
ERBB2-amplified IBCs compared to ERBB2-amplified
NIBCs, SQLE (8q24.13) was gained or amplified in IBCs
Table 1 Genes altered by CNA with a frequency significantly different in ER+ and ER- ERBB2-amplified tumors
ER status of ERBB2-amplified tumors Targeted by gene CNA Altered genes Location CNV, Type#
ER- gain GDPD4 11q13.5
PAK1
CLNS1A
ER+ gain ADAM5P 8p11.23 Variation_1197, CNV
ADAM3A Variation_1779, CNV
TRPS1* 8q23.3 Variation_42116, InDel
BC040336
EIF3H
AL713790 8q24.11
SLC30A8
MED30
SAMD12 8q24.12 Variation_3145, CNV
FAM91A1 8q24.13
C8orf54
C8orf78
BC015129
TMEM65 Variation_52365, CNV
CR933665
RNF139 Variation_28765, InDel
TATDN1
MTSS1 Variation_43549, CNV
LOC157381
SQLE Variation_34021, InDel
KIAA0196
NSMCE2 Variation_41128, Indel
TRIB1
BC038572 8q24.21
FAM84B Variation_37296, Inversion
PVT1* Variation_8615, CNV
BC009730
amplification C8ORFK23 8q24.13
LOC650095
LOC90110 17q12 Variation_5006, CNV
FBXL20 CNVVariation_5006, CNV
CASC3 17q21.1
gain or amplification ZNF572 8q24.13
AK093407
loss or deletion SAMD11 1p36.33 Variation_30362, CNV
AGRN Variation_2294, CNV
GNB1 Variation_3276, CNV
AK128532 1p36.32
RNF212 4p16.3 Variation_30190, CNV
B4GALNT4 11p15.5 Variation_29880, CNV
*TRPS1 and PVT1 gene expression was in proportion to their CNA
# The information about the presence of CNV and the type of genomic variations (CNV, InDel, inversion...) was extracted from hg17 and hg18.
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by CNA in the two populations. This suggests that the
upregulation of SQLE associated with gain or amplifica-
tion could be a specific oncogenic mechanism in IBC
whereas the upregulation of RSF1could be explained by
others mechanisms such as hypomethylation of its
promoter.
ERBB2 amplification, gene expression, protein expression
and phsophorylation
ERBB2 status was assessed by IHC. First, we used the
HerceptTest and the TAB250 antibodies to evaluate the
ERBB2 expression but also to compare their detection
in relation with the ERBB2-amplification. Therefore,
using HerceptTest on 40 ERBB2-amplified BCs (Figure
5), 97.5% (39/40) of the samples were ERBB2-positive
(Additionnal file 1-Tables S7-S8A). They were classified
2+ (1 ERBB2-like, 1 luminal A, 2 basal and 1 normal-
like) and 3+ (15 ERBB2-like, 2 luminal A, 2 luminal B, 2
basal, 6 normal-like, 7 not assigned). Only one (luminal
A) was 0+ (Additionnal file 1-Table S8). TAB250 on 35
ERBB2-amplified BCs detected 23 positive samples
(66%) (Additionnal file 1-Tables S8-S9A). A total of 35
tumors were analyzed with both HercepTest and
TAB250. Among the 23 samples positive for TAB250,
all (100%) were also HerceptTest positive (Additionnal
file 1-Table S8). Conversely, among the 12 tumors nega-
tive for TAB250, only one was HerceptTest negative
(Additionnal file 1-Table S8).
ERBB2 copy number averages evaluated by aCGH in
tumors positive with HerceptTest (N = 39), TAB250
(N = 23) or both were equal to 11.3, 13.3 and 13.3
respectively (Additionnal file 1-Table S8). Tumors nega-
tive for HerceptTest (N = 1), TAB250 (N = 12) or both
were equal to 8.8, 7.8 and 8.8, respectively. Among sam-
ples positive with both HerceptTest and TAB250, 41%
Figure 4 Supervised classification of ER+ and ER- ERBB2-amplified BCs based on RNA expression data. Left, classification of 51 samples
using a 638-gene expression signature (listed in Additionnal file 1-Table S7C). Top panel, matrix of expression data. Each row of the data matrix
represents a gene and each column represents a sample. Expression levels are depicted according to the color scale shown at the bottom. Red
and green indicate expression levels respectively above and below the median. The magnitude of deviation from the median is represented by
the color saturation. Genes are ordered from top to bottom by their decreasing signal-to-noise ratio. Tumor samples are ordered from left to
right according to the decreasing correlation coefficient of their expression profile with the median profile of the ER+ samples (Bottom panel).
The orange line indicates the threshold 0 that separates the two predicted classes of samples, “ER+ class” (to the left) and “ER- class” (to the
right). The middle panel indicates the observed ER status of tumors (black square, ER+; white square, ER-). Right, correlation between the
molecular grouping based on the combined expression of the 638 genes (predicted status) and the observed ER status of samples.
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Page 10 of 18(16/39) and 48% (11/23) were subtyped as ERBB2-like,
respectively. Similarly, among samples positive with
both HerceptTest and TAB250, 5% (2/39) and 4% (1/23)
were subtyped as luminal B, respectively. Taken
together, these results suggest a linear relationship
between ERBB2 gene amplification and its gene and
protein expressions for almost half of ERBB2-amplified
samples. This relationship was not perfect for 4/12
amplified samples negative with TAB250 were ERBB2-
like, respectively. However, we noted that they were all
3+ with HerceptTest. The only ERBB2-amplified sample
negative with HerceptTest (T11348) was luminal A.
Unfortunately, no sufficient material (T11348) associated
with a correct morphology was available to confirm its
ERBB2 amplification status by using silver in situ hybri-
dization (SISH, Ventana). The IHC pattern of this sam-
ple showing also FOXA1 positivity was in agreement
with its luminal A phenotype [40,41], suggesting that no
mismatching had occurred for this case.
The expression of pERBB2 could help predict clinical
response of ERBB2-positive BCs to trastuzumab or lapa-
tinib [8,42,43]. pERBB2 status was evaluated by IHC on
22 ERBB2-amplified samples (Figure 5) and was
detected in 17/22 (Additionnal file 1-Tables S8-S9A).
Among the 17 samples, 17 (100%) and 14 (82%) were
also HerceptTest and TAB250 positive, respectively.
This result suggests a good correlation between ERBB2
expression and phosphorylation status (Table 2).
IGF1R and EGFR expression in ERBB2-amplified tumors
Expression levels of insulin-like growth factor type 1
receptor (IGF1R), epidermal growth factor receptor
(EGFR), and ERBB2 have been linked to clinical
outcome in breast and other solid tumors [44]. We
Figure 5 Immunohistochemical expression analysis in ERBB2-amplified tumors. Two exemples of IHC profile of ERBB2-amplified cases.
The IHC profiles show in ERBB2-amplified ERBB2-positive (a-f) an ERBB2 expression defined as 3+ with Herceptest (a) and TAB250 (b) as well
as a cytoplasmic positivity of pERBB2 (c) a cell membrane positivity of IFG1R (d) and an absence of FOXA1 (e) and EGFR (f) expression. The
IHC profiles show in ERBB2-amplified ERBB2-negative (g-m) an ERBB2 expression defined as 0+ with Herceptest (h) and TAB250 (i) as well as
a weak cytoplasmic positivity of pERBB2 (j) no positivity of cell membrane of IFG1R (k), a strong nuclear expression of FOXA1 (l) and an
absence of EGFR (m).
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of IGF1R and EGFR protein expression in ERBB2-ampli-
fied patients.
IGF1R status was assessed in 30 ERBB2-amplified BCs
for which ERBB2 IHC status had been determined (Fig-
ure 5). Seven (23%) tumors expressed IGF1R (Addition-
nal file 1-Tables S8-S9A); all of them also expressed
ERBB2 (all HerceptTest 3+). Similarly, EGFR status was
assessed in 37 ERBB2-amplified BCs for which ERBB2
status was established. Twelve (32%) tumors expressed
EGFR (Additionnal file 1-Tables S8-S9A); all of them
expressed ERBB2 (HerceptTest: 9 3+ and 3 2+). IGF1R/
EGFR/ERBB2 coexpression was rarely observed (1/29)
while IGF1R/ERBB2 and EGFR/ERBB2 coexpression was
observed in 24% (7/29) and 33% (12/36) of cases,
respectively (Table 2). IGF1R/EGFR/pERBB2 coexpres-
sion was never observed (0/24) while IGF1R/pERBB2
and EGFR/pERBB2 coexpression was observed in 14%
(2/14) and 41% (7/17), respectively (Table 2). These
results are in agreement with the signaling cross-talk
described between EGFR family members and IGF1R in
maintaining the malignant phenotype [45].
FOXA1 is frequently coexpressed with ERBB2 in ERBB2-
amplified tumors
Forkhead transcription factor FOXA1 is involved in
mammary tumorigenesis and may be involved in a
cross-talk between hormonal receptors and ERBB2 [41].
To define a potential impact of FOXA1 expression in
ERBB2-amplified BCs, FOXA1 status was assessed by
IHC in 22 ERBB2-amplified BCs for which ERBB2 IHC
status had been determined (Figure 5). Fifteen (68%)
tumors expressed FOXA1 (Additionnal file 1-Tables S8-
S9A). FOXA1 expression was observed in 67% (14/21)
of ERBB2-positive tumors. In details, 1 (luminal A) and
14 tumors (1 luminal B, 9 ERBB2-like, 3 normal-like
and 1 not assigned) were classified as 0+ and 3+, respec-
tively. This result is in agreement with a recent study
showing that FOXA1 was expressed in all ERBB2-posi-
tive breast cancer cell lines [46]. FOXA1 expression was
observed in 71% (12/17) of pERBB2-tumors (Table 2).
Clinical features and protein expression analysis of ER+
and ER- ERBB2-amplified BCs
We finally compared clinical features and EGFR, FOXA1,
ERBB2, pERBB2 and IGF1R protein expression in ER+
(N = 22) and ER- (N = 25) ERBB2-amplified tumors
(Additionnal file 1-Table S9B). Compared to ER+ cases,
ER- cases were all PR-negative (p < 0.001), more often
EGFR-positive (p < 0.05) and ERBB2-like. ER- BCs had a
tendency (higher grade and 5 years-MFS [p = 0.059 and
p = 0.06, respectively]) to have a poorer prognosis and
were more likely to recur than ER+ BCs (Additionnal file
1-Table S9B).
Discussion
We used high-resolution aCGH and DNA microarrays
to define the genome and gene expression profiles of
BCs with 17q12-q21-amplification. Results concerning
cell lines are given for information to the scientific
community.
At this stage, we would not discuss any relation
between ERBB2 amplicon size and resistance to trastu-
zumab because of small numbers.
Genomic alterations of ERBB2-amplified tumors
We identified 18 regions targeted by CNAs in ERBB2-
amplified BCs. As expected, the most frequent encom-
passed the region of ERBB2-amplification previously
defined [17,37] and included NEUROD2, PPP1R1B,
STARD3, TCAP, PNMT, PERLD1, ERBB2, C17ORF37,
GRB7 and IKZF3/ZNFN1A3 17q12 genes (>85% of
17q12-q21-amplified samples) (Additionnal file 1-Table
S5). ERBB2-C17orf37-GRB7 was the core region system-
atically included in all 17q12-q21-amplified samples.
We noted that 8q24.1, 11q13.4-q14.1, 14q11.1-q11.2,
17q21.1-q21.2 and 19q12 regions of amplification were
associated with ERBB2-amplified BCs. Some of these
regions were previously reported co-amplified in breast
cancers [1] (Additionnal file 1-Table S6A). A recent
study [47] showed correlations between the presence of
such amplicons and molecular subtypes in grade 3 inva-
sive ductal BCs (Additionnal file 1-Table S6A) suggest-
ing that (i) the two amplified subregions within 8q24.1
amplifications (with a frequ e n c yo f5 0 %a n d2 1 % )c o u d
be associated with basal and non-basal subtypes, respec-
tively; (ii) the 11q13.4-q14.1 amplification (with a
frequency of 15%) could be associated exclusively
with the luminal subtype; (iii) the 14q12, 14q12-q13.1
and 14q23.2-q23.3 amplifications (with an identical
Table 2 Co-expression frequency and association
between protein expressions
Protein combinations Co-expression*
N (%)
pERBB2/ERBB2 81% (17/21)
IGF1R/ERBB2 24% (7/29)
IGF1R/pERBB2 14% (2/14)
EGFR/ERBB2 33% (12/36)
EGFR/pERBB2 41% (7/17)
IGF1R/EGFR 11% (1/9)
IGF1R and EGFR/ERRB2 3% (1/29)
IGF1R and EGFR/pERBB2 0% (0/14)
FOXA1/ERBB2 67% (14/21)
FOXA1/pERBB2 71% (12/17)
*Co-expression means that tumors were positive for both factors.
†Expression
scores evaluated according to scales defined in material and methods to
examine correlations.
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the ERBB2 subtype; (iv) the 17q21.1-q21.2 amplification
(with a frequency of 100%) coud be associated exclu-
sively with the ERBB2 subtype. In contrast, for other
17q amplicons (17q21.32, 17q21.32-q22, 17q23.1q23.2
and 17q23.3) we did not found any association with
ERBB2-amplified tumors; (v) the two amplified subre-
gions within 19q12 amplifications (with frequencies of
12% and 16%, respectively) coud be associated exclu-
sively with the basal subtype.
We showed a genomic heterogeneity of ERBB2-ampli-
fied BCs with respect to with ER+ and ER- status. The
genomic profiles of ER+ and ER- ERBB2-amplified
tumors were previously reported [18]. Gains of 17q23-
q24 and losses of 1p39, 1p36, 1p35, 1p32, 7q21-q22,
7q34, 7q36.1-q36.3, 9p21.3, and 11q13.5 were more fre-
quent in ER+ cases while gain of 5p15-p12 was asso-
ciated with ER- cancers. None of these regions was
observed similarly altered in our study (Additionnal file
1-Table S6A).
We identified 37 genes whose expression levels were
deregulated in proportion to CNA. Some of these genes
were similarly found in previous studies [1,48] (SQLE,
KIAA0196, STARD3, PERLD1, ERBB2, GRB7, CCNE1).
In ER+ ERBB2-amplified BCs, only PVT1 was com-
monly found with this study [1]. Similarly, 24 genes
(65%) from another previous study [38] were common
with our candidates (Additionnal file 1-Table S6A).
Seventeen (SQLE, DDX52, MRPL45, SOCS7, PSMB3,
PIP4K2B, CCDC49, LASP1, FBXL20, MED1, STARD3,
P E R L D 1 ,E R B B 2 ,C 1 7 o r f 3 7 ,G R B 7 ,R A P G E F L 1 ,a n d
CCNE1)a n dt h r e e( KIAA0196, RSF1, INTS4) were asso-
ciated with ERBB2 and luminal molecular subtypes,
respectively; KCTD21 and PERLD1 were associated with
both ERBB2 and luminal molecular subtypes. MAL2,
WIPF2 and CDC6 were not associated with any specific
molecular subtype [38].
The difference in the number of genes found in our
study compared to previous studies [1,38,47,48] could
be explained by the high resolution aCGH 244K we
used (whereas 2464 BAC arrays [OncoBAC array] and
32K BAC arrays were previously used [[1] and
[38,47,48], respectively]) and by integrating gene level
with gene expression analysis.
Within the 17q12-q21 region, amplification of ERBB2,
STARD3, TCAP, PNMT, PERLD1, C17orf37, GRB7,
GSDML, PSMD3 and THRAP4 genes have been
reported to correlate with gene expression [1,15,28,36].
Amplification and overexpression of other genes (such
as GRB7, C17orf37 and STARD3)o ft h e1 7 q 1 2r e g i o n
could contribute to tumor growth [18,19]. C17orf37
open reading frame encodes a 12-kDa protein of
unknown function. C17ORF37 protein expression is
linked with ERBB2-amplification in most cases, however,
it has also been observed in breast carcinomas that do
not overexpress ERBB2, and particularly in early stage
and infiltrating lobular carcinomas that typically do not
overexpress ERBB2 [49]. This suggests that C17ORF37
could represent an additional target for cancer therapy.
Growth factor receptor-bound protein 7 (GRB7) is an
adaptor-type signaling protein that binds to a variety of
cell surface receptor tyrosine kinases including EGFR
and ERBB2 [50] to mediate downstream signaling path-
ways. GRB7 may facilitate ERBB2-mediated signal trans-
duction and tumor formation [51] and has been
suggested as a therapeutic target [19].
Seventeen other regions were affected by CNAs with a
lower frequency in ERBB2-amplified tumors. Some of
them have been found involved in mammary carcino-
genesis. Loss of 4p16.3 (Additionnal file 1-Table S6A)
was telomeric to the deleted R4 region located between
D4S43 and D4S127 (4p16.3) previously observed in
breast carcinomas [52]. It included CTBP1,w h o s e
decreased expression has been associated with migra-
tory, invasive potential of melanoma cells [53]. However,
we did not observe downregulated CTBP1 expression in
proportion to the deletion of this region. The 4q13.3
gain/amplification targeted 20 genes, including those
encoding EGFR ligands EPEG, EREG, AREG and BTC,
which could play a critical role in oncogenesis [54]. Loss
of 8p23.3, a region affected by deletion in both breast
and pancreatic cell lines [55] targeted 10 genes including
ARHGEF10, a potential tumor suppressor [55]. How-
ever, this gene did not show downregulated expression
in proportion to copy number loss.
Gain and amplification of 8q23.3-q24.21 targeted 31
genes. This region delimited from centromere to telomere
by TRPS1 and PVT1 contains MYC, two colorectal cancer
risk loci, rs16892766 (8q23.3) [56] and rs6983267
(8q24.21), and one breast cancer risk locus rs13281615
(8q24.21) [57]. rs6983267 is a good candidate for a multi-
cancer susceptibility marker [58]. A strong association for
rs13281615 was observed for ER+, PR+, and low grade
breast tumors [57]. To date, no relationship has been
reported between the presence of these loci and the
8q23.3-q24.21 amplification. Coamplification of MYC and
PVT1 seem to correlate with rapidly growing and progres-
sive breast cancer and has been associated with poor out-
come in postmenopausal or ERBB2-positive BC patients
[59]. Only C8orf53, MAL2, LOC286052, SQLE and
KIAA0196 were upregulated in proportion to copy num-
ber gain or amplification of the 8q23.3-q24.21 region in
the ERBB2-amplified tumors. The MAL2 gene was pre-
viously found amplified and overexpressed in breast and
other cancers, yet the significance of this is unknown.
SQLE overexpression was found in high-risk ER+ stage
I/II BCs [60] but SQLE mRNA overexpression was not dif-
ferent in ER+ and ER- ERBB2-amplified tumors.
Sircoulomb et al. BMC Cancer 2010, 10:539
http://www.biomedcentral.com/1471-2407/10/539
Page 13 of 18Amplification of 8q24.11-13 (THRAP6, DCC1, SQLE,
SPG8) and 11q14.1 (NDUFC2, ALG8, USP35) have been
associated with poor prognosis in a novel subtype of
high-grade ER- tumors [36]. Within 11q13.5-q14.1,
RSF1, INTS4 and KCTD21 were upregulated in propor-
tion to copy number gain/amplification in the ERBB2-
amplified tumors. RSF1, a chromatin-remodeling gene,
was identified as a potential oncogene in ovarian serous
carcinoma [61].
Within 19q12, CCNE1 was upregulated in proportion
to copy number gain or amplification. CCNE1 expres-
sion in breast cancer cells has been associated with ER-
status, ERBB2 expression, high tumor grade and high
proliferation index [62]. Breast cancer-associated var-
iants have been found in four cell cycle genes including
CCNE1 rs997669 [63].
ER- and ER + ERBB2-amplified breast tumors
Expression profiling studies [11,64] have also suggested
that ERBB2-amplified BCs constitute a heterogeneous
group that could be subdivided according to ER status:
ER+ ERBB2-amplified BCs fall into the luminal B clus-
ter; and ER- ERBB2-amplified BCs constitute the actual
ERBB2-like subtype.
Specific genetic aberrations and expression are indeed
characteristic of ER+ and ER- ERBB2 BCs. Upregulated
ESR1, GATA3, ERBB4, TFF1 and TFF3 gene expression
was associated with ER+ ERBB2-amplified tumors.
These genes are typically associated with the luminal
subtype, suggesting that the ER+ ERBB2-amplified
tumors could be a branch of the luminal tumors and
could share the same progenitor. Only TRPS1 and PVT1
were identified as candidate oncogenes in ER+ ERBB2-
amplified tumors. TRPS1 encodes a zinc finger tran-
scription factor widely expressed in human tissues and
overexpressed in BCs [65]. PVT1 is most likely a non-
coding RNA that acts independently of MYC and, when
amplified and overexpressed, increases proliferation and
inhibits apoptosis [66]. Seven miRNAs cover PVT1 [67]
and could play a role in mammary oncogenesis.
The ER- ERBB2-amplified samples were mainly
ERBB2-like (88%) (Additionnal file 1-Table S9B) and
upregulated IGF2R, GATA6, TGFA and EGFR.T h e
canonical WNT/b-catenin signaling pathway was asso-
ciated with ER- ERBB2-amplified tumors. b-catenin is a
substrate of ERBB2 kinase. Geldanamycin could be
included in the panel of potential therapeutic tools
because it destabilizes ERBB2 tyrosine kinase and sup-
presses WNT/b-catenin signaling in ERBB2-overexpres-
sing cells [68].
IBCs and NIBCs with ERBB2-amplification
We found that the size of ERBB2 amplicon is smaller in
IBC than in NIBC and that this difference is independent
of the ER status. Perhaps the rapid evolution of IBC pre-
vents the construction of large amplicons.
Twelve genes were deregulated in ERBB2-amplified
IBCs. Ten of them (SNIP, MLLT6, CISD3, PCGF2,
PSMB3, PIP4K2B, FBXL20, STARD3, GRB7 and RARA)
are located within the 17q12-q21-amplicon suggesting
that this region has a strong influence on the IBC phe-
notype in ERBB2-amplified BCs. Some of the 10 down-
regulated genes are potential tumor suppressor genes.
The SNIP protein is tyrosine phosphorylated upon
integrin-dependent adhesion or EGF treatment, with a
potential role as a downstream effector of cell matrix
and growth factor signaling that suppresses tumorigenic
properties of breast cancer cells [69]. PCGF2 is a poly-
comb protein that could act as a tumor suppressor [70].
Markers and targets in ERBB2-amplified BCs
The response of ERBB2-amplified BCs to anthracyclines
m a yb ei n f l u e n c e db yt h ep r e s e n c eo fTOP2A in the
17q12-q21-amplicon [20,21,37]. Although TOP2A ampli-
fication was described as a discriminatory feature
between ER+ and ER- ERBB2-amplified BCs [48] we
were not able to confirm this result because the statisti-
cal analysis was not applicable to our data. (Data not
shown).
IGF1R+ or EGFR+ ERBB2-amplified tumors were all
ERBB2+ while IGF1R and EGFR were rarely coex-
pressed. Previous studies have suggested that interac-
tions among families of growth factor receptors enhance
the malignant behavior of tumor cells [71]. Furthermore,
cross-talk between IGF1R and EGFR or ERBB2 has been
implicated in the development of resistance to EGFR
and ERBB2 inhibitors [46]. FOXA1 was frequently coex-
pressed with ERBB2 in ERBB2-amplified tumors.
FOXA1 is essential for optimal expression of half of ER-
related genes. FOXA1 expression correlates with luminal
A subtype and good prognosis [72]. We did not find any
association between FOXA1 expression and the out-
come of patients with ERBB2-amplified tumors.
Conclusions
O u rs t u d ys h o w st h a tE R B B 2B C sa r eh e t e r o g e n e o u s
with respect to clinical, immunohistochemical and mole-
cular factors and identifies features that may be useful in
the design of therapeutical approaches of these poor
prognosis cancers.
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Additionnal file 1: Supplementary Tables. Table S1 - Clinical and
histological features of the 54 profiled ERBB2-amplified breast tumors.
Table S2 - Proteins tested by IHC: antibodies and experimental
conditions. Table S3 - Clinical and histological features of the two aCGH-
clustered ERBB2-amplified tumor groups defined through the whole
genome. Table S4 - Clinical and histological features of the two aCGH-
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STAT3] genomic segment. Table S5 - Definition of the ERBB2 amplicon
score. Table S6A - Significant altered regions found in the 54 samples
harboring the 17q12-q21-amplification (defined by the score index with
a threshold of 10
-3). Table S6B - Gene expression deregulation
frequencies of genes included in ERBB2-amplicon. Table S7A - Integrated
genome analysis of ER- and ER+ ERBB2-amplified tumors. Table S7B-
Clinical and histological features of the two clustered ERBB2-amplified
tumor groups defined using gene expression data. Table S7C - Genes
with expression significantly different in ER- and ER+ ERBB2-amplified
tumors. Table S7D - Canonical pathways associated with ER+ and ER-
expression signature in ERBB2-amplified BCs. Table S7E - Regions
significantly altered by CNA in ERBB2-amplified IBC and NIBC. Table S8 -
Transversal analysis of ERBB2-amplified BCs. Table S9A - Clinical features
and protein expression analysis of ERBB2-amplified BCs. Table S9B -
Clinical features and protein expression analysis of ER+ and ER- ERBB2-
amplified BCs.
Additionnal file 2: Supplementary Material.
Additionnal file 3: Figure S1: Genomic profiles of chromosome 17
in ERBB2-amplified primary breast tumors and breast cancer cell
lines. A-C - Regional 17q12-q21 amplification centered on the ERBB2
locus observed in the 54 studied BCs. S1A and S1B-C show genomic
profiles of chromosome 17 established with CGH analytics® software
(Agilent Technologies) in IBC and NIBC samples, respectively. The 17q12-
q21 amplification (log2 ratio >1) was found as single abnormality or
associated with other various copy number aberrations along
chromosome 17. The arrow indicates the 17q12-q21-amplicon centered
on the ERBB2 locus. D - Regional 17q12-q21-amplification centered on
the ERBB2 locus observed in the 14 studied breast cancer cell lines.
Genomic profiles of chromosome 17 were established as defined in
Additionnal file 3-Figures S1A-C.
Additionnal file 4: Figure S2: Whole-genome expression profiling of
ERBB2-amplified BCs. A - Hierarchical clustering of 51 samples and
13,114 genes/ESTs with significant variation in mRNA expression level
across the samples. Each row of the data matrix represents a gene and
each column represents a sample. Expression levels are depicted
according to the color scale shown at the bottom. Red and green
indicate expression levels respectively above and below the median. The
magnitude of deviation from the median is represented by the color
saturation. The dendrogram of samples (above matrixes) represents
overall similarities in gene expression profiles and is zoomed in B. B -
Dendrograms of samples. Top, Two large groups of tissue samples
(designated I to II) are evidenced by clustering and delimited by the
orange solid vertical line (see also Additionnal file 1-Table S7B). Below
the dendrogram, Below the dendrogram, from the top to the bottom,
name of tumors are given and the two first rows indicate their ER and
IGF1R status (black square, ER+ or IGF1R+; white square, ER- or IGF1R-) of
patients, while the last row indicates the molecular subtypes. The third
row indicates the gene expression molecular subtypes as previously
defined [13] using specific colored squares (luminal A: dark blue; luminal
B: sky blue; basal: red; ERBB2-like: pink; normal-like: green and not
assigned: white).
Additionnal file 5: Figure S3: Canonical pathways associated with
ER+ and ER- ERBB2-amplified BCs. Histograms show canonical
pathways associated with either ER+ or ER- ERBB2-amplified BCs.
Established by Ingenuity® pathways analysis software, they show relevant
proteins (Additionnal file 1-Table S7D) encoded by genes associated with
the ER+/ER- ERBB2-amplified BCs molecular signature (Additionnal file 1-
Table S7C). Color codes and corresponding legends are indicated in the
box located to the left at the top of the figure.
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